Astex
Pre-Approval PRO BETAStale Activity
No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 6/27/2023
Pipeline by Phase
Therapeutic Focus
Clinical Trials (25)
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Started: 3/16/2017
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Started: 1/13/2017
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Started: 2/15/2018
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Started: 3/19/2015
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Started: 6/27/2023
SGI-110 in Combination With Carboplatin in Ovarian Cancer
Started: 9/1/2012
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Started: 12/1/2012
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Started: 3/1/2011
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
Started: 5/1/2011
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Started: 1/4/2011
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Started: 10/28/2014
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Started: 10/1/2010
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Started: 6/12/2020
Thorough QT Assessment of Cedazuridine in Healthy Subjects
Started: 7/1/2021
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
Started: 5/20/2020
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Started: 5/1/2008
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Started: 11/1/2010
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
Started: 7/20/2020
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Started: 12/21/2020
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Started: 10/1/2012
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Started: 2/1/2009
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Started: 9/1/2012
A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
Started: 7/23/2020